\BOOKMARK [0][-]{chapter.1}{Introduction}{}% 1
\BOOKMARK [1][-]{section.1.1}{Cancer Research in the Post-Genomic Era}{chapter.1}% 2
\BOOKMARK [2][-]{subsection.1.1.1}{Cancer as a Global Health Concern}{section.1.1}% 3
\BOOKMARK [3][-]{section*.4}{Genetics and Molecular Biology in Cancers}{subsection.1.1.1}% 4
\BOOKMARK [2][-]{subsection.1.1.2}{The Human Genome Revolution}{section.1.1}% 5
\BOOKMARK [3][-]{section*.5}{The First Human Genome Sequence}{subsection.1.1.2}% 6
\BOOKMARK [3][-]{section*.6}{Expectations of Genomics}{subsection.1.1.2}% 7
\BOOKMARK [2][-]{subsection.1.1.3}{Technologies to Enable Genetics Research}{section.1.1}% 8
\BOOKMARK [3][-]{section*.7}{DNA Sequencing and Genotyping Technologies}{subsection.1.1.3}% 9
\BOOKMARK [3][-]{section*.8}{Microarrays and Quantitative Technologies}{subsection.1.1.3}% 10
\BOOKMARK [3][-]{section*.9}{Massively Parallel ``Next Generation'' Sequencing Technologies}{subsection.1.1.3}% 11
\BOOKMARK [4][-]{section*.10}{Established Sequencing Technologies}{section*.9}% 12
\BOOKMARK [4][-]{section*.11}{Emerging Sequencing Technologies}{section*.9}% 13
\BOOKMARK [3][-]{section*.12}{Bioinformatics as an Interdisciplinary Approach to Genomics Data}{subsection.1.1.3}% 14
\BOOKMARK [2][-]{subsection.1.1.4}{Follow-up Large-Scale Genomics Projects}{section.1.1}% 15
\BOOKMARK [2][-]{subsection.1.1.5}{Cancer Genomes}{section.1.1}% 16
\BOOKMARK [3][-]{section*.13}{The Cancer Genome Atlas Project}{subsection.1.1.5}% 17
\BOOKMARK [3][-]{section*.14}{The International Cancer Genome Consortium}{subsection.1.1.5}% 18
\BOOKMARK [3][-]{section*.15}{Sub-population and Cell Line projects}{subsection.1.1.5}% 19
\BOOKMARK [2][-]{subsection.1.1.6}{Genomic Cancer Medicine}{section.1.1}% 20
\BOOKMARK [3][-]{section*.16}{Cancer Genes and Driver Mutations}{subsection.1.1.6}% 21
\BOOKMARK [3][-]{section*.17}{Personalised or Precision Cancer Medicine}{subsection.1.1.6}% 22
\BOOKMARK [4][-]{section*.18}{Molecular Diagnostics and Pan-Cancer Medicine}{section*.17}% 23
\BOOKMARK [3][-]{section*.19}{Targeted Therapeutics and Pharmacogenomics}{subsection.1.1.6}% 24
\BOOKMARK [4][-]{section*.20}{Targeting Oncogenic Driver Mutations}{section*.19}% 25
\BOOKMARK [3][-]{section*.21}{Systems and Network Biology}{subsection.1.1.6}% 26
\BOOKMARK [4][-]{section*.22}{ Network Medicine, and Polypharmacology}{section*.21}% 27
\BOOKMARK [1][-]{section.1.2}{A Synthetic Lethal Approach to Cancer Medicine}{chapter.1}% 28
\BOOKMARK [2][-]{subsection.1.2.1}{Synthetic Lethal Genetic Interactions}{section.1.2}% 29
\BOOKMARK [2][-]{subsection.1.2.2}{Synthetic Lethal Concepts in Genetics}{section.1.2}% 30
\BOOKMARK [2][-]{subsection.1.2.3}{Studies of Synthetic Lethality}{section.1.2}% 31
\BOOKMARK [3][-]{section*.23}{Synthetic Lethal Pathways and Networks}{subsection.1.2.3}% 32
\BOOKMARK [4][-]{section*.24}{Conservation and Evolution of Synthetic Lethality}{section*.23}% 33
\BOOKMARK [2][-]{subsection.1.2.4}{Synthetic Lethal Concepts in Cancer}{section.1.2}% 34
\BOOKMARK [2][-]{subsection.1.2.5}{Clinical Impact of Synthetic Lethality in Cancer}{section.1.2}% 35
\BOOKMARK [2][-]{subsection.1.2.6}{High-throughput Screening for Synthetic Lethality}{section.1.2}% 36
\BOOKMARK [3][-]{section*.25}{Examples of High-throughput Synthetic Lethal Screens}{subsection.1.2.6}% 37
\BOOKMARK [2][-]{subsection.1.2.7}{Computational Prediction of Synthetic Lethality}{section.1.2}% 38
\BOOKMARK [1][-]{section.1.3}{E-cadherin as a Synthetic Lethal Target}{chapter.1}% 39
\BOOKMARK [2][-]{subsection.1.3.1}{The CDH1 gene and it's Biological Functions}{section.1.3}% 40
\BOOKMARK [3][-]{section*.26}{Cytoskeleton}{subsection.1.3.1}% 41
\BOOKMARK [3][-]{section*.27}{Extracellular and Tumour Micro-Environment}{subsection.1.3.1}% 42
\BOOKMARK [3][-]{section*.28}{Cell-Cell Adhesion and Signalling}{subsection.1.3.1}% 43
\BOOKMARK [2][-]{subsection.1.3.2}{CDH1 as a Tumour \(and Invasion\) Suppressor}{section.1.3}% 44
\BOOKMARK [3][-]{section*.29}{Breast Cancers and Invasion}{subsection.1.3.2}% 45
\BOOKMARK [2][-]{subsection.1.3.3}{Hereditary Diffuse Gastric Cancer and Lobular Breast Cancer}{section.1.3}% 46
\BOOKMARK [2][-]{subsection.1.3.4}{Somatic Mutations}{section.1.3}% 47
\BOOKMARK [3][-]{section*.30}{Mutation Rate}{subsection.1.3.4}% 48
\BOOKMARK [3][-]{section*.31}{Co-occuring Mutations}{subsection.1.3.4}% 49
\BOOKMARK [2][-]{subsection.1.3.5}{Models of CDH1 loss in cell lines}{section.1.3}% 50
\BOOKMARK [1][-]{section.1.4}{Summary and Research Direction of Thesis}{chapter.1}% 51
\BOOKMARK [0][-]{section.1.4}{References}{}% 52
